HomeCompareAKRO vs EPRT

AKRO vs EPRT: Dividend Comparison 2026

AKRO yields 3.66% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $38.0K in total portfolio value
10 years
AKRO
AKRO
● Live price
3.66%
Share price
$54.65
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$463.02
Full AKRO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — AKRO vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAKROEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AKRO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AKRO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AKRO
Annual income on $10K today (after 15% tax)
$311.07/yr
After 10yr DRIP, annual income (after tax)
$393.57/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,521.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AKRO + EPRT for your $10,000?

AKRO: 50%EPRT: 50%
100% EPRT50/50100% AKRO
Portfolio after 10yr
$44.4K
Annual income
$6,651.87/yr
Blended yield
14.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AKRO
Analyst Ratings
10
Buy
4
Hold
Consensus: Buy
Price Target
$54.67
+0.0% upside vs current
Range: $54.00 — $56.00
Altman Z
54.7
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AKRO buys
0
EPRT buys
0
No recent congressional trades found for AKRO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAKROEPRT
Forward yield3.66%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$25.4K$63.4K
Annual income after 10y$463.02$12,840.73
Total dividends collected$4.2K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$54.67$35.50

Year-by-year: AKRO vs EPRT ($10,000, DRIP)

YearAKRO PortfolioAKRO Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$11,066$365.97$11,205$505.18$139.00EPRT
2$12,219$378.48$12,672$682.46$453.00EPRT
3$13,465$390.58$14,490$930.48$1.0KEPRT
4$14,810$402.25$16,786$1,282.69$2.0KEPRT
5$16,260$413.48$19,753$1,791.56$3.5KEPRT
6$17,822$424.27$23,677$2,541.64$5.9KEPRT
7$19,505$434.61$29,008$3,672.99$9.5KEPRT
8$21,314$444.52$36,463$5,425.08$15.1KEPRT
9$23,260$453.99$47,238$8,221.57$24.0KEPRT
10$25,352$463.02$63,385$12,840.73$38.0KEPRT

AKRO vs EPRT: Complete Analysis 2026

AKROStock

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Full AKRO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AKRO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AKRO vs SCHDAKRO vs JEPIAKRO vs OAKRO vs KOAKRO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.